[go: up one dir, main page]

DE60314658D1 - Verfahren zur identifizierung von die funktionen von polypeptid-galnac-transferasen modulierenden agentien, solche agentien umfassende pharmazeutische zusammensetzungen und verwendung solcher agentien zur herstellung von arzneimitteln - Google Patents

Verfahren zur identifizierung von die funktionen von polypeptid-galnac-transferasen modulierenden agentien, solche agentien umfassende pharmazeutische zusammensetzungen und verwendung solcher agentien zur herstellung von arzneimitteln

Info

Publication number
DE60314658D1
DE60314658D1 DE60314658T DE60314658T DE60314658D1 DE 60314658 D1 DE60314658 D1 DE 60314658D1 DE 60314658 T DE60314658 T DE 60314658T DE 60314658 T DE60314658 T DE 60314658T DE 60314658 D1 DE60314658 D1 DE 60314658D1
Authority
DE
Germany
Prior art keywords
agents
galnac
disclosed
methods
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60314658T
Other languages
English (en)
Inventor
Henrik Clausen
Eric Paul Bennett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlycoZym ApS
Original Assignee
GlycoZym ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlycoZym ApS filed Critical GlycoZym ApS
Application granted granted Critical
Publication of DE60314658D1 publication Critical patent/DE60314658D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE60314658T 2002-11-08 2003-11-07 Verfahren zur identifizierung von die funktionen von polypeptid-galnac-transferasen modulierenden agentien, solche agentien umfassende pharmazeutische zusammensetzungen und verwendung solcher agentien zur herstellung von arzneimitteln Expired - Lifetime DE60314658D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42520402P 2002-11-08 2002-11-08
PCT/DK2003/000763 WO2004042075A2 (en) 2002-11-08 2003-11-07 Inactivated ga1 - nac - transferases, methods for inhibitors of such transferases and their use

Publications (1)

Publication Number Publication Date
DE60314658D1 true DE60314658D1 (de) 2007-08-09

Family

ID=32312943

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60314658T Expired - Lifetime DE60314658D1 (de) 2002-11-08 2003-11-07 Verfahren zur identifizierung von die funktionen von polypeptid-galnac-transferasen modulierenden agentien, solche agentien umfassende pharmazeutische zusammensetzungen und verwendung solcher agentien zur herstellung von arzneimitteln

Country Status (6)

Country Link
US (2) US20050026266A1 (de)
EP (1) EP1558728B1 (de)
AT (1) ATE365794T1 (de)
AU (1) AU2003275952A1 (de)
DE (1) DE60314658D1 (de)
WO (1) WO2004042075A2 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) * 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
DE60336555D1 (de) * 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
BRPI0408358A (pt) * 2003-03-14 2006-03-21 Neose Technologies Inc polìmeros hidrossolúveis ramificados e seus conjugados
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP2055189A1 (de) 2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylierungsverfahren und durch die Verfahren hergestellte Proteine/Peptide
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
ES2380093T3 (es) * 2003-05-09 2012-05-08 Biogenerix Ag Composiciones y métodos para la preparación de mutantes de glucosilación de la hormona del crecimiento humana
US9005625B2 (en) * 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) * 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7842661B2 (en) * 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
US8633157B2 (en) * 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
CA2547140A1 (en) * 2003-11-24 2005-06-09 Neose Technologies, Inc. Glycopegylated erythropoietin
US20080015142A1 (en) * 2003-12-03 2008-01-17 Defrees Shawn Glycopegylated Follicle Stimulating Hormone
US20070254836A1 (en) * 2003-12-03 2007-11-01 Defrees Shawn Glycopegylated Granulocyte Colony Stimulating Factor
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
CN101072789B (zh) * 2004-01-08 2013-05-15 生物种属学股份公司 肽的o-连接的糖基化
JP2008512085A (ja) * 2004-06-03 2008-04-24 ネオス テクノロジーズ インコーポレイティッド 切断型ＧａｌＮＡｃＴ２ポリペプチドおよび核酸
EP1759006B1 (de) * 2004-06-21 2011-12-07 Exelixis, Inc. Galnts als modifikatoren des igfr-weges und verwendungsverfahren
EP1771066A2 (de) 2004-07-13 2007-04-11 Neose Technologies, Inc. Remodellierung von verzweigtem peg und klykolysierung von glucagonähnlichem peptide-1 glp-1
US20090292110A1 (en) * 2004-07-23 2009-11-26 Defrees Shawn Enzymatic modification of glycopeptides
US8268967B2 (en) * 2004-09-10 2012-09-18 Novo Nordisk A/S Glycopegylated interferon α
ES2566670T3 (es) 2004-10-29 2016-04-14 Ratiopharm Gmbh Remodelación y glucopegilación del factor de crecimiento de fibroblastos (FGF)
WO2006074279A1 (en) * 2005-01-06 2006-07-13 Neose Technologies, Inc. Glycoconjugation using saccharyl fragments
MX2007008229A (es) * 2005-01-10 2007-09-11 Neose Technologies Inc Factor estimulador de colonias de granulocitos glicopegilado.
EP2386571B1 (de) 2005-04-08 2016-06-01 ratiopharm GmbH Zusammensetzungen und Verfahren zur Herstellung von Glycosylierungsmutanten eines Proteaseresistenten menschlichen Wachstumshormons
US20110003744A1 (en) * 2005-05-25 2011-01-06 Novo Nordisk A/S Glycopegylated Erythropoietin Formulations
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007041495A2 (en) * 2005-09-29 2007-04-12 University Of California, San Diego Dampening humoral and innate immunity by inhibition of ppgalnact-1
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
ES2534465T3 (es) 2005-11-15 2015-04-23 Glycofi, Inc. Producción de glucoproteínas con O-glucosilación reducida
WO2007120638A2 (en) * 2006-04-12 2007-10-25 President And Fellows Of Harvard College Methods and compositions for modulating glycosylation
US9187532B2 (en) * 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
MX2009003470A (es) * 2006-10-04 2009-04-14 Novo Nordisk As Azucares y glicopeptidos pegilados enlazados a glicerol.
WO2008040362A2 (en) 2006-10-04 2008-04-10 Københavns Universitet Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
EA017770B1 (ru) * 2007-04-03 2013-03-29 Биодженерикс Аг Способы лечения с использованием гликопэгилированного g-csf
CN101778937A (zh) * 2007-06-04 2010-07-14 诺和诺德公司 使用n-乙酰葡糖胺转移酶的o-联糖基化
CN101778859B (zh) * 2007-06-12 2014-03-26 诺和诺德公司 改良的用于生产核苷酸糖的方法
US8524444B2 (en) * 2007-06-15 2013-09-03 President And Fellows Of Harvard College Methods and compositions for detections and modulating O-glycosylation
US7968811B2 (en) * 2007-06-29 2011-06-28 Harley-Davidson Motor Company Group, Inc. Integrated ignition and key switch
US8207112B2 (en) * 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
CA2711503A1 (en) * 2008-01-08 2009-07-16 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
EP2626080A3 (de) 2008-02-27 2014-03-05 Novo Nordisk A/S Konjugierte Faktor-VIII-Moleküle
WO2010141074A2 (en) 2009-06-01 2010-12-09 President And Fellows Of Harvard College O-glcnac transferase inhibitors and uses thereof
EP2470903A4 (de) * 2009-08-25 2013-02-13 Oncotherapy Science Inc Gen und polypeptid für brustkrebs
WO2013006758A1 (en) 2011-07-06 2013-01-10 President And Fellows Of Harvard College Diphosphate mimetics and uses thereof
AU2013295815A1 (en) * 2012-07-24 2015-02-05 Cedars-Sinai Medical Center A novel method to detect resistance to chemotherapy in patients with lung cancer
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
WO2016077567A1 (en) * 2014-11-12 2016-05-19 Tumorend, Llc Compositions, methods and treatments for inhibiting cell adhesion and virus binding and penetration
DE102016201235A1 (de) 2016-01-28 2017-08-03 Minimax Gmbh & Co. Kg Nebellöschanlage

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643758A (en) * 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
US5268364A (en) * 1991-12-12 1993-12-07 The Biomembrane Institute Method for inhibiting selectin-dependent adhesion of leukocytes and platelets by O-glycosylation modification
DE60128218D1 (de) * 2000-05-11 2007-06-14 Glycozym Aps METHODEN ZUR MODELIERUNG DIE FUNKTION VON POLYPEPTID GalNAc TRANSFERASEN UND ZURSCREENING SUBSTANZEN DAFÜR
US7338932B2 (en) * 2000-05-11 2008-03-04 Glycozym Aps Methods of modulating functions of polypeptide GalNAc-transferases and of screening test substances to find agents herefor, pharmaceutical compositions comprising such agents and the use of such agents for preparing medicaments

Also Published As

Publication number Publication date
US20080038809A1 (en) 2008-02-14
WO2004042075A2 (en) 2004-05-21
AU2003275952A8 (en) 2004-06-07
EP1558728A2 (de) 2005-08-03
WO2004042075A3 (en) 2004-09-10
US20050026266A1 (en) 2005-02-03
EP1558728B1 (de) 2007-06-27
ATE365794T1 (de) 2007-07-15
AU2003275952A1 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
DE60314658D1 (de) Verfahren zur identifizierung von die funktionen von polypeptid-galnac-transferasen modulierenden agentien, solche agentien umfassende pharmazeutische zusammensetzungen und verwendung solcher agentien zur herstellung von arzneimitteln
EA201100688A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
EA200970557A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
ATE456372T1 (de) Haftklebende n,o-carboxy methylchitosan beschichtungen, die die befestigung von zellen und proteinen mit den sustraten hemmen.
GEP20105074B (en) Pyrimidinyl aryl urea derivatives being fgf inhibitors
IL181271A0 (en) Triazolophthalazine derivatives and pharmaceutical compositions containing the same
NO20055714L (no) Inhibitorer av fosfatidylinositol 3-kinase
ATE383358T1 (de) 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren
DE69918089D1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
DE602004022187D1 (de) 4-(pyrazol-3-ylamino)pyrimidinderivate zur verwendung bei der behandlung von krebs
HUE10161767T1 (hu) Immunpotenciáló kompozíciók, amelyek anti-PD-L1 antitesteket tartalmaznak
DE60236605D1 (de) Zusammensetzungen und deren verwendung zur behandlung von krebs
ATE399522T1 (de) Hydrogel-klebstoffe zur verwendung auf fasern besetzten oberflächen
NO20061656L (no) 2,4 di(hetero)-arylamino-pyrimidin derivaer som ZAP-70 og/aller SYK inhibitorer
ATE404574T1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
DE602006014949D1 (de) Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs
BRPI0416690A (pt) derivados de pirrol
BRPI0512547A (pt) pirimidinas
DE60016625D1 (de) Zusammensetzung enthaltend einen inhibitor der signaltransduktion von heterotrimerischen g-proteinen in kombination mit einem anderen anti-krebs mittel zu einer therapeutischen verwendung in der krebsbehandlung
DE502007005636D1 (de) Triaza-benzoäeüazulenderivate zur behandlung von tumoren
ATE319668T1 (de) Verfahren zur synthese von (2s)-indolin-2- carbonsäure, und verwendung in der synthese von perindopril
ATE427933T1 (de) Inhibitoren der bindungder chemokine i-tac bzw. sdf-1 an den ccxckr2-rezeptor
WO2001004354A3 (en) Use of ras inhibitors of inhibiting muscle atrophy
DE602004023939D1 (de) Kristalliner vap-1 und verwendung
DE60237243D1 (de) Nadelförmige kristalle von diharnstoffderivaten die sich von hydrazin ableiten und ihre verwendung zur veränderung der rheology in überzugszusammensetzungen und klebstoffen

Legal Events

Date Code Title Description
8332 No legal effect for de